New drug combo aims to tackle tough lung cancer
NCT ID NCT07362940
First seen Jan 23, 2026 · Last updated Jun 23, 2026 · Updated 21 times
Summary
This early-stage trial is testing whether two oral drugs, GEN-725 and Dositinib, can safely shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer. About 110 participants will receive the combination daily until their disease worsens or side effects become too severe. The study focuses on safety and how well the drugs work against the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
-
Cancer Hospital Affiliated to Shandong First Medical University (Shandong Cancer Hospital, Shandong cancer prevention and treatment institute)
NOT_YET_RECRUITINGJinan, China
-
Henan Cancer Hospital
NOT_YET_RECRUITINGZhengzhou, China
-
Hunan Cancer Hospital
NOT_YET_RECRUITINGChangsha, China
-
The First Affiliated Hospital of Xiamen University
NOT_YET_RECRUITINGXiamen, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GEN-725 tablets and Dositinib mesylate tablets
What this could lead to
If it works, this combination could offer a new treatment option for people with a specific type of lung cancer that has stopped responding to other therapies.
What could go wrong
This is an early-phase trial with only 110 participants, so the drug combination may not prove effective or could cause unexpected side effects. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.